Jason Mouabbi

403 total citations
41 papers, 205 citations indexed

About

Jason Mouabbi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jason Mouabbi has authored 41 papers receiving a total of 205 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Jason Mouabbi's work include Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (12 papers) and HER2/EGFR in Cancer Research (11 papers). Jason Mouabbi is often cited by papers focused on Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (12 papers) and HER2/EGFR in Cancer Research (11 papers). Jason Mouabbi collaborates with scholars based in United States, Germany and Switzerland. Jason Mouabbi's co-authors include Rachel M. Layman, Debasish Tripathy, Gabriel N. Hortobágyi, Bora Lim, Tarik Hadid, Amy M. Fowler, C. Kent Osborne, Elisabeth G.E. de Vries, Akshara Singareeka Raghavendra and Lanell M. Peterson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jason Mouabbi

32 papers receiving 204 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jason Mouabbi United States 7 113 100 64 51 24 41 205
David Riseberg United States 6 103 0.9× 58 0.6× 43 0.7× 45 0.9× 24 1.0× 8 166
Luca Boscolo Bielo Italy 10 132 1.2× 79 0.8× 63 1.0× 40 0.8× 58 2.4× 27 211
Marcelle Goldner Cesca Brazil 6 223 2.0× 99 1.0× 76 1.2× 88 1.7× 27 1.1× 18 272
Tetsuhiro Yoshinami Japan 6 116 1.0× 50 0.5× 53 0.8× 18 0.4× 33 1.4× 48 174
Vicente Carañana Spain 7 227 2.0× 127 1.3× 90 1.4× 27 0.5× 22 0.9× 20 262
Laura L. Michel Germany 9 120 1.1× 72 0.7× 60 0.9× 21 0.4× 32 1.3× 37 194
Carmine Valenza Italy 10 185 1.6× 87 0.9× 86 1.3× 65 1.3× 76 3.2× 47 311
Mei-Lin Ah-See United Kingdom 9 128 1.1× 53 0.5× 52 0.8× 116 2.3× 40 1.7× 21 243
Tormund S. Njølstad Norway 8 109 1.0× 57 0.6× 46 0.7× 44 0.9× 77 3.2× 11 386
Sylvain Dureau France 10 115 1.0× 68 0.7× 47 0.7× 32 0.6× 38 1.6× 19 214

Countries citing papers authored by Jason Mouabbi

Since Specialization
Citations

This map shows the geographic impact of Jason Mouabbi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Mouabbi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Mouabbi more than expected).

Fields of papers citing papers by Jason Mouabbi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Mouabbi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Mouabbi. The network helps show where Jason Mouabbi may publish in the future.

Co-authorship network of co-authors of Jason Mouabbi

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Mouabbi. A scholar is included among the top collaborators of Jason Mouabbi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Mouabbi. Jason Mouabbi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Middleton, Lavinia P., George H. Perkins, Gary J. Whitman, et al.. (2025). Immediate and ipsilateral recurrence rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ. Breast Cancer Research and Treatment. 213(2). 225–235.
2.
Lu, Yen‐Shen, Paolo Tarantino, Christine Brezden‐Masley, et al.. (2025). 351P Real-world (RW) analysis of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation in patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB). ESMO Open. 10. 104922–104922. 1 indexed citations
3.
Gouda, Mohamed A., Ecaterina E. Dumbrava, Timothy A. Yap, et al.. (2025). Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 31(7). 1268–1274. 8 indexed citations
4.
Mouabbi, Jason, Funda Meric‐Bernstam, Azadeh Nasrazadani, et al.. (2024). The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast.. Journal of Clinical Oncology. 42(16_suppl). 1044–1044. 1 indexed citations
5.
Mouabbi, Jason, et al.. (2024). INCIDENCE AND RISK FACTORS FOR PNEUMONITIS DUE TO TRASTUZUMAB DERUXTECAN IN FEMALES WITH BREAST CANCER. CHEST Journal. 166(4). A3513–A3514.
6.
Tarantino, Paolo, Joyce O’Shaughnessy, W Janni, et al.. (2024). 245P Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis. Annals of Oncology. 35. S317–S318. 1 indexed citations
7.
Kuerer, Henry M., Gaiane M. Rauch, Savitri Krishnamurthy, et al.. (2023). 243MO Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial. Annals of Oncology. 34. S280–S280. 1 indexed citations
8.
Ulaner, Gary A., David A. Mankoff, Amy S. Clark, et al.. (2023). Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol. Journal of Nuclear Medicine. 64(3). 351–354. 46 indexed citations
9.
10.
Valero, Vicente, Jason Mouabbi, Rashmi K. Murthy, et al.. (2023). 132P Neoadjuvant zanidatamab for stage I node-negative HER2- positive breast cancer (BC). ESMO Open. 8(1). 101471–101471. 3 indexed citations
11.
Mouabbi, Jason, Akshara Singareeka Raghavendra, Matthias Christgen, et al.. (2023). Abstract P3-05-04: Absence of Lobular Carcinoma In Situ, a Poor Prognostic Marker in Invasive Lobular Carcinoma. Cancer Research. 83(5_Supplement). P3–5. 1 indexed citations
12.
Mouabbi, Jason, Funda Meric‐Bernstam, Nikita Kotlov, et al.. (2023). Genomic characterization of the GATA3 mutational landscape in breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1039–1039.
13.
Mouabbi, Jason, et al.. (2023). Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. The Oncologist. 29(3). 213–218. 3 indexed citations
14.
Batra, Harsh Vardhan, Jason Mouabbi, Qingqing Ding, Ayşegül A. Şahin, & Maria Gabriela Raso. (2023). Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights. Cancers. 15(22). 5491–5491. 14 indexed citations
15.
Mouabbi, Jason, Akshara Singareeka Raghavendra, Roland L. Bassett, et al.. (2023). Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. European Journal of Cancer. 191. 113250–113250. 2 indexed citations
16.
Mouabbi, Jason, Funda Meric‐Bernstam, Nikita Kotlov, et al.. (2023). Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas.. Journal of Clinical Oncology. 41(16_suppl). 579–579. 2 indexed citations
17.
Mouabbi, Jason, et al.. (2022). Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Research and Treatment. 193(2). 253–264. 49 indexed citations
18.
19.
Mouabbi, Jason, C. Kent Osborne, Rachel Schiff, & Mothaffar F. Rimawi. (2021). Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer. Breast Cancer Research and Treatment. 190(2). 189–201. 14 indexed citations
20.
Mouabbi, Jason, et al.. (2018). Intravenous Iron for the Treatment of Steroid-Refractory Idiopathic Thrombocytopenic Purpura. Blood. 132(Supplement 1). 3768–3768. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Riseberg Breakdown of academic impact, for papers by Luca Boscolo Bielo Breakdown of academic impact, for papers by Marcelle Goldner Cesca Breakdown of academic impact, for papers by Tetsuhiro Yoshinami Breakdown of academic impact, for papers by Vicente Carañana Breakdown of academic impact, for papers by Laura L. Michel Breakdown of academic impact, for papers by Carmine Valenza Breakdown of academic impact, for papers by Mei-Lin Ah-See Breakdown of academic impact, for papers by Tormund S. Njølstad Breakdown of academic impact, for papers by Sylvain Dureau
Rankless by CCL
2026